C.R. Bard, Inc. (NYSE:BCR)‘s stock had its “hold” rating reissued by equities research analysts at Cowen and Company in a report issued on Friday. They presently have a $317.00 price target on the medical instruments supplier’s stock. Cowen and Company’s price objective indicates a potential downside of 5.53% from the company’s current price.

Other analysts have also issued research reports about the stock. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. BidaskClub upgraded shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 8th. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Zacks Investment Research lowered shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, BMO Capital Markets restated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a strong buy rating to the stock. C.R. Bard currently has an average rating of “Hold” and an average target price of $292.00.

Shares of C.R. Bard (NYSE BCR) traded up $8.77 during trading on Friday, hitting $335.55. 105,153 shares of the company traded hands, compared to its average volume of 478,414. The stock has a market capitalization of $24.46 billion, a PE ratio of 28.98 and a beta of 0.53.

C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.96 by $0.06. The company had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The firm’s revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the business earned $2.64 earnings per share. equities analysts expect that C.R. Bard will post 11.89 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “C.R. Bard, Inc. (BCR) Stock Rating Reaffirmed by Cowen and Company” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/c-r-bard-inc-bcr-stock-rating-reaffirmed-by-cowen-and-company/1676435.html.

In other news, VP Betty D. Larson sold 5,906 shares of C.R. Bard stock in a transaction dated Friday, October 20th. The shares were sold at an average price of $330.16, for a total value of $1,949,924.96. Following the sale, the vice president now owns 10,753 shares in the company, valued at $3,550,210.48. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now owns 31,445 shares in the company, valued at approximately $10,022,464.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 136,568 shares of company stock worth $43,932,079. Company insiders own 0.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in BCR. Farallon Capital Management LLC acquired a new position in C.R. Bard during the second quarter worth about $463,101,000. Alpine Associates Management Inc. acquired a new position in C.R. Bard during the second quarter worth about $265,663,000. Pentwater Capital Management LP acquired a new position in C.R. Bard during the second quarter worth about $139,088,000. York Capital Management Global Advisors LLC acquired a new position in C.R. Bard during the second quarter worth about $122,678,000. Finally, CNH Partners LLC acquired a new position in C.R. Bard during the second quarter worth about $116,100,000. Institutional investors and hedge funds own 79.27% of the company’s stock.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Analyst Recommendations for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.